RAIN,Rain Therapeutics Inc. | Healthcare

Healthcare

RAIN

All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities

Rain Therapeutics Inc.RAIN

USD

- At close

USD

- Until the end

The complete list of US stocks

MAX

Overview >

% Change

Description >

Rain Oncology Inc., a late-stage precision oncology company, engages in developing therapies that target oncogenic drivers to genetically select patients in the United States.

The company's lead product candidate is milademetan, a small molecule oral inhibitor of MDM2-p53 complex that reactivates p53.

The company was formerly known as Rain Therapeutics Inc. and changed its name to Rain Oncology Inc. in December 2022.

Rain Oncology Inc. was incorporated in 2017 and is headquartered in Newark, California.

Latest News >

Why Is Vaccine Maker Emergent BioSolutions Stock Trading Higher On Tuesday? (UPDATED)

Jul 3, 2024

Editor’s Note: The story has been updated to replace the erroneous content published earlier. Tuesday, Emergent BioSolutions Inc. ( EBS ) received more than $250 million in contract modifications from the Administration for Strategic Preparedness and Response (ASPR) at the United States Department of Health and Human Services to deliver millions of doses of four medical countermeasures. These contract modifications will help ensure...

Identiv Receives Stockholder Approval for Asset Sale Transaction With Vitaprotech

Jul 3, 2024

06:09 AM EDT, 07/03/2024 (MT Newswires) -- Identiv ( INVE ) said late Tuesday its stockholders approved the asset sale transaction with security solutions provider Vitaprotech for $145 million in cash. About 96% of the shares voted were in favor of the asset sale proposal as recommended by the company's board, representing about 72% of the company's outstanding shares. The...

Patriot Battery Metals COO Retires

Jul 3, 2024

06:12 AM EDT, 07/03/2024 (MT Newswires) -- Patriot Battery Metals ( PMETF ) on Tuesday said COO Blair Way retired on June 30. Way will continue to serve on the board as a non-executive director and provide advisory services on a consulting basis over the coming months to ensure a smooth transition. The company also appointed John Drapack as director...

"Failed" Australian corporate watchdog should be spilt in two, senate inquiry finds

Jul 3, 2024

(Reuters) - Australia's corporate watchdog should be split into two after comprehensively failing in its role, including by not taking action against offenders and focusing more on managing its reputation, a senate committee report showed on Wednesday. The Australian Securities and Investment Commission's (ASIC) scope was too broad for it to be effective and efficient and the government should consider...